DE2848965A1 - Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine - Google Patents

Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine

Info

Publication number
DE2848965A1
DE2848965A1 DE19782848965 DE2848965A DE2848965A1 DE 2848965 A1 DE2848965 A1 DE 2848965A1 DE 19782848965 DE19782848965 DE 19782848965 DE 2848965 A DE2848965 A DE 2848965A DE 2848965 A1 DE2848965 A1 DE 2848965A1
Authority
DE
Germany
Prior art keywords
neisseria meningitidis
membrane proteins
detergent
minutes
vaccine containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19782848965
Other languages
German (de)
English (en)
Inventor
Gerhard Dipl Chem Guthoehrlein
Torsten Bertil Dr Helting
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Behringwerke AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke AG filed Critical Behringwerke AG
Priority to DE19782848965 priority Critical patent/DE2848965A1/de
Priority to ES485715A priority patent/ES485715A1/es
Priority to DE7979104391T priority patent/DE2962526D1/de
Priority to EP79104391A priority patent/EP0011243B1/de
Priority to AT79104391T priority patent/ATE857T1/de
Priority to JP14456179A priority patent/JPS5566519A/ja
Priority to DK475779A priority patent/DK154841C/da
Priority to AU52682/79A priority patent/AU533386B2/en
Priority to IL58673A priority patent/IL58673A/xx
Priority to CA000339541A priority patent/CA1142083A/en
Priority to MX10131579U priority patent/MX5941E/es
Publication of DE2848965A1 publication Critical patent/DE2848965A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE19782848965 1978-11-11 1978-11-11 Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine Withdrawn DE2848965A1 (de)

Priority Applications (11)

Application Number Priority Date Filing Date Title
DE19782848965 DE2848965A1 (de) 1978-11-11 1978-11-11 Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
ES485715A ES485715A1 (es) 1978-11-11 1979-11-06 Procedimiento mejorado para la preparacion de proteinas de membranas
DE7979104391T DE2962526D1 (en) 1978-11-11 1979-11-08 Process for preparing membrane proteins from neisseria meningitidis and vaccines containing them
EP79104391A EP0011243B1 (de) 1978-11-11 1979-11-08 Verfahren zur Herstellung von Membranproteinen aus Neisseria meningitidis und diese enthaltende Vaccine
AT79104391T ATE857T1 (de) 1978-11-11 1979-11-08 Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine.
JP14456179A JPS5566519A (en) 1978-11-11 1979-11-09 Manufacture of membrane protein and vaccine containing it
DK475779A DK154841C (da) 1978-11-11 1979-11-09 Fremgangsmaade til fremstilling af membranproteiner ud fra neisseria meningitidis
AU52682/79A AU533386B2 (en) 1978-11-11 1979-11-09 Isolation of membrane proteins from neisseria meningitidis and vaccines containing same
IL58673A IL58673A (en) 1978-11-11 1979-11-09 Process for the isolation of membrane proteins from neisseria meningitidis and vaccines containing same
CA000339541A CA1142083A (en) 1978-11-11 1979-11-09 Process for the isolation of membrane proteins from neisseria meningitidis and vaccines containing same
MX10131579U MX5941E (es) 1978-11-11 1979-11-09 Procedimiento mejorado para la preparacion de membranoproteinas a partir de neisseria meningitidis grupo"b"

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19782848965 DE2848965A1 (de) 1978-11-11 1978-11-11 Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine

Publications (1)

Publication Number Publication Date
DE2848965A1 true DE2848965A1 (de) 1980-05-22

Family

ID=6054405

Family Applications (2)

Application Number Title Priority Date Filing Date
DE19782848965 Withdrawn DE2848965A1 (de) 1978-11-11 1978-11-11 Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
DE7979104391T Expired DE2962526D1 (en) 1978-11-11 1979-11-08 Process for preparing membrane proteins from neisseria meningitidis and vaccines containing them

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE7979104391T Expired DE2962526D1 (en) 1978-11-11 1979-11-08 Process for preparing membrane proteins from neisseria meningitidis and vaccines containing them

Country Status (9)

Country Link
EP (1) EP0011243B1 (https=)
JP (1) JPS5566519A (https=)
AT (1) ATE857T1 (https=)
AU (1) AU533386B2 (https=)
CA (1) CA1142083A (https=)
DE (2) DE2848965A1 (https=)
DK (1) DK154841C (https=)
ES (1) ES485715A1 (https=)
IL (1) IL58673A (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4317811A (en) 1980-09-11 1982-03-02 Merck & Co., Inc. Herpes simplex type 1 subunit vaccine
US12109243B2 (en) 2017-09-08 2024-10-08 Evelo Biosciences, Inc. Bacterial extracellular vesicles

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1221626A (en) * 1982-12-02 1987-05-12 Milan Blake Iga binding protein
US7118757B1 (en) 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
BR9910749A (pt) 1998-05-29 2001-02-13 Chiron Corp Composições e vacinas imunogênicas combinadas para meningites b e c e método de induzir uma resposta imune por administração da mesma
EP2270173B1 (en) 1999-05-19 2016-01-06 GlaxoSmithKline Biologicals SA Combination neisserial compositions
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
PT2289545T (pt) 2000-01-17 2016-09-06 Glaxosmithkline Biologicals Sa Vacina de omv suplementada contra meningococos
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
EP1524991A1 (en) 2002-08-02 2005-04-27 GlaxoSmithKline Biologicals S.A. Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
CU23313A1 (es) 2002-11-27 2008-09-25 Inst Finlay Ct De Investigacia Mã0/00todo de obtenciã"n de estructuras cocleares. composiciones vacunales y adyuvantes basados en estructuras cocleares y sus intermediarios
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
EP1706481A2 (en) * 2003-12-23 2006-10-04 GlaxoSmithKline Biologicals S.A. Vaccine
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
DE602007003596D1 (de) 2006-06-12 2010-01-14 Glaxosmithkline Biolog Sa Impfstoff
WO2009050586A1 (en) 2007-10-19 2009-04-23 Novartis Ag Meningococcal vaccine formulations
CN102356089B (zh) 2008-02-21 2014-02-19 诺华股份有限公司 脑膜炎球菌fHBP多肽
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
JP2012512240A (ja) 2008-12-17 2012-05-31 ノバルティス アーゲー ヘモグロビン受容体を含む髄膜炎菌ワクチン
CA2765112A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
US20110076300A1 (en) 2009-08-27 2011-03-31 Mariagrazia Pizza Hybrid Polypeptides Including Meningococcal fHBP Sequences
CN102740882A (zh) 2009-08-27 2012-10-17 诺华有限公司 含有铝、寡核苷酸和聚阳离子的佐剂
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
CN102724988B (zh) 2009-09-30 2014-09-10 诺华股份有限公司 脑膜炎球菌fHBP多肽的表达
CA2779816A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
SG10201501980SA (en) 2009-12-15 2015-05-28 Novartis Ag Homogeneous suspension of immunopotentiating compounds and uses thereof
EP2544714A1 (en) 2010-03-10 2013-01-16 GlaxoSmithKline Biologicals S.A. Vaccine composition
CN102802662A (zh) 2010-03-18 2012-11-28 诺华有限公司 用于脑膜炎球菌血清组b的含佐剂疫苗
AU2011232421B2 (en) 2010-03-23 2015-08-13 Novartis Ag Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc.
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
BR112013005626B1 (pt) 2010-09-10 2022-07-26 Glaxosmithkline Biologicals Sa Meningococo, processo para a preparação de uma cepa meningocócica, vesículas de membrana externa, composição farmacêutica imunogênica, e, uso de uma composição
EP2707009A1 (en) 2011-05-12 2014-03-19 Novartis AG Antipyretics to enhance tolerability of vesicle-based vaccines
JP5957541B2 (ja) 2012-02-02 2016-07-27 ノバルティス アーゲー 髄膜炎菌における増加したタンパク質発現のためのプロモータ
JP2015517089A (ja) 2012-03-08 2015-06-18 ノバルティス アーゲー タンパク質ベースの髄膜炎菌ワクチンのためのインビトロ有効性アッセイ
MX357538B (es) 2012-06-14 2018-07-13 Novartis Ag Vacunas para meningococo de serogrupo x.
US9526776B2 (en) 2012-09-06 2016-12-27 Glaxosmithkline Biologicals Sa Combination vaccines with serogroup B meningococcus and D/T/P
US9764027B2 (en) 2012-09-18 2017-09-19 Glaxosmithkline Biologicals Sa Outer membrane vesicles
JP6786394B2 (ja) 2014-02-28 2020-11-18 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 改変髄膜炎菌ｆＨｂｐポリペプチド
US12161707B2 (en) 2016-09-02 2024-12-10 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
BR112021007668A2 (pt) 2018-11-06 2021-07-27 Glaxosmithkline Biologicals S.A. composições imunogênicas
EP3799884A1 (en) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
GB202115072D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
GB202211033D0 (en) 2022-07-28 2022-09-14 Glaxosmithkline Biologicals Sa Purification process

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4317811A (en) 1980-09-11 1982-03-02 Merck & Co., Inc. Herpes simplex type 1 subunit vaccine
US12109243B2 (en) 2017-09-08 2024-10-08 Evelo Biosciences, Inc. Bacterial extracellular vesicles

Also Published As

Publication number Publication date
IL58673A (en) 1983-02-23
JPS5566519A (en) 1980-05-20
ATE857T1 (de) 1982-04-15
DE2962526D1 (en) 1982-05-27
EP0011243A1 (de) 1980-05-28
CA1142083A (en) 1983-03-01
DK154841C (da) 1989-06-05
DK475779A (da) 1980-05-12
IL58673A0 (en) 1980-02-29
JPS6350332B2 (https=) 1988-10-07
DK154841B (da) 1988-12-27
ES485715A1 (es) 1980-05-16
AU533386B2 (en) 1983-11-24
AU5268279A (en) 1980-05-15
EP0011243B1 (de) 1982-04-14

Similar Documents

Publication Publication Date Title
EP0011243B1 (de) Verfahren zur Herstellung von Membranproteinen aus Neisseria meningitidis und diese enthaltende Vaccine
DE2902136C2 (de) Verfahren zum Herstellen von Interferon
US4271147A (en) Process for the isolation of membrane proteins from Neisseria meningitidis and vaccines containing same
DE69626022T3 (de) Verfahren zur industriellen herstellung eines japanischen enkephalitis impfstoffes, und so erhaltener impfstoff
DE69124235T3 (de) Reinigung und verwendung von pertactin, eines bordetella pertussis aussenmembranproteins
DE69023648T3 (de) Herstellung eines virusimpfstoffes
DE3834729A1 (de) Verwendung von zink-oder eisenhydroxid zur adjuvierung von antigenloesungen und auf diese weise adjuvierte antigenloesungen
EP0222974B1 (de) Verfahren zur Herstellung eines Tollwutimpfstoffes und nach diesem Verfahren erhaltener Impfstoff
DE2461439A1 (de) Schuetzendes pertussis-antigen und verfahren zu seiner herstellung sowie jenes enthaltende mittel
DE3024282A1 (de) Vakzinierende glycopeptid-antigenfraktion mit grosser immunisierungsfaehigkeit, isoliert aus kulturen pathogener keime, verfahren zur isolierung dieser fraktion und diese enthaltende vakzinen
DE3152621C2 (https=)
DD202623A5 (de) Verfahren zur herstellung von sporen-polyosiden
DE3782356T2 (de) Reinigungsverfahren der proteischen antigene von bordetella-bakterien zur gewinnung eines azellularen vakzins.
DE3541044A1 (de) Neues, allgemein anwendbares antigen (psc-a) gegen pseudomonas aeruginosa, das als mittel zum schutz gegen pseudomonas aeruginosa-infektion wirkt
DE2425997A1 (de) Verfahren zur herstellung von abgeschwaechtem katzenfiebervakzin
EP0445710B1 (de) Verwendung von Zink-Calciumhydroxid, Lecithin und PAO zur Adjuvierung von Antigenlösungen und auf diese Weise adjuvierte Antigenlösungen
DE2845745C2 (https=)
EP0491125B1 (de) Impfstoffe gegen equine Herpesviren und ihre Herstellung
DE69413952T2 (de) Extraktion von zellgebundenem protein von bordetella
DE2737060C2 (de) Escherichia coli-Neurotoxin
DE3005495C2 (de) Herstellung von Fragmenten von Viren mit Lipidhülle und sie enthaltende Arzneimittelzubereitungen
DE1667929A1 (de) Vakzine
DE967241C (de) Verfahren zum Trennen von lebendem Virus von virusfremden Eiweissstoffen
DE2033946C2 (de) Lebendimpfstoff gegen infektiöse pustulöse Vulvovaginitis [IPV] und infektiöse bovine Rhinotracheitis [IBR]
AT105476B (de) Verfahren zur Herstellung eines Masernschutzimpfstoffes und des dazu erforderlichen Nährbodens.

Legal Events

Date Code Title Description
8130 Withdrawal